SCHEDULE: Vanguard Group Reports 0% CorMedix Stake Post-Realignment

The Vanguard Group reports 0% beneficial ownership in CorMedix Inc. following an internal realignment that disaggregated reporting.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for CorMedix Inc. common stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of CorMedix Inc. common stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions will report beneficial ownership separately, disaggregated from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these newly disaggregated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for CorMedix Inc., as the change in Vanguard's reported ownership is due to an internal organizational realignment rather than a strategic divestment based on CorMedix's performance or prospects.

Future Outlook

No specific future outlook or guidance for CorMedix Inc. is provided in this filing, as it pertains to a change in beneficial ownership reporting by The Vanguard Group.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that large asset managers like The Vanguard Group frequently undergo internal restructurings or reallocations of reporting responsibilities. Such changes can lead to adjustments in reported beneficial ownership without necessarily reflecting a change in investment thesis for the underlying company. This is a common procedural update for large institutional investors.

Stakeholder Impact

• Shareholders: May initially perceive a large institutional investor's reported ownership dropping to zero as negative, but the explanation clarifies it's a reporting change, not a full divestment, which should mitigate concerns.

Next Steps

• The Vanguard Group's subsidiaries and/or business divisions will report beneficial ownership separately on a disaggregated basis.

Key Dates

Recommendation

The filing primarily details a procedural change in how The Vanguard Group reports its beneficial ownership due to an internal realignment, resulting in a reported 0% stake in CorMedix Inc. This does not reflect a change in investment thesis or performance of CorMedix itself. Therefore, without additional information on CorMedix's fundamentals, a 'hold' recommendation is appropriate as this filing provides no new information to warrant a change in investment strategy.

Keywords

CorMedix Inc, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, SEC filing, investment realignment